Novo Nordisk A/S (NVO.N)

NVO.N on New York Stock Exchange

45.28USD
21 Oct 2014
Price Change (% chg)

$0.33 (+0.73%)
Prev Close
$44.95
Open
$44.85
Day's High
$45.31
Day's Low
$44.68
Volume
106,311
Avg. Vol
185,462
52-wk High
$49.10
52-wk Low
$33.05

NVO.N

Chart for NVO.N

About

Novo Nordisk A/S is a healthcare company. The Company is engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. It is engaged in diabetes care. It has a range of diabetes product portfolio, including a portfolio of modern insulins and the first human once-daily GLP-1 analog. In addition,... (more)

Overall

Beta: 0.97
Market Cap (Mil.): $96,983.40
Shares Outstanding (Mil.): 2,112.56
Dividend: 0.83
Yield (%): 1.83

Financials

  NVO.N Industry Sector
P/E (TTM): 27.35 32.90 33.54
EPS (TTM): 1.66 -- --
ROI: 65.79 18.34 17.61
ROE: 71.98 19.01 18.42
Search Stocks

Analysts see U.S. approval of Novo Nordisk's obesity drug by year-end

COPENHAGEN - The U.S. Food and Drug Administration is likely to approve Novo Nordisk's new drug to treat obesity this year, analysts said after wide expectations of an FDA decision late on Monday were not met.

21 Oct 2014

Novo Nordisk's NNIT to announce IPO next week - Berlingske daily

COPENHAGEN, Oct 15 - NNIT, the information technology unit of Danish pharmaceutical company Novo Nordisk , is expected to announce plans for an initial public offering (IPO) on the Nasdaq Copenhagen exchange next week, daily Berlingske reported on Wednesday.

15 Oct 2014

Novo Nordisk's next big idea: a once-weekly insulin shot

COPENHAGEN - Denmark's Novo Nordisk, the world's largest insulin maker, is betting on a new way to stay ahead in the $40 billion-plus diabetes market by trying to develop the world's first once-weekly insulin injection.

01 Oct 2014

NORDIC STOCKS - Factors to watch on Sept 19

HELSINKI, Sept 19 - The following stocks may be affected by newspaper reports and other factors on Friday:

19 Sep 2014

Novo's Ryzodeg effective in type 2 diabetes treatment: study

COPENHAGEN - Novo Nordisk's type 2 diabetes treatment Ryzodeg has proved effective in providing good blood sugar control with fewer injections than a so-called basal-bolus treatment, according to new data from a late-stage study.

18 Sep 2014

Novo's Ryzodeg effective in type 2 diabetes treatment -study

COPENHAGEN, Sept 18 - Novo Nordisk's type 2 diabetes treatment Ryzodeg has proved effective in providing good blood sugar control with fewer injections than a so-called basal-bolus treatment, according to new data from a late-stage study.

18 Sep 2014

NORDIC STOCKS-Factors to watch on Sept 17

COPENHAGEN, Sept 17 - The following stocks may be affected by newspaper reports and other factors on Wednesday:

17 Sep 2014

Study shows Novo's new diabetes drug effective and safe for children

COPENHAGEN - Novo Nordisk's new long-acting insulin Tresiba has been shown to be effective and safe for long-term use in children and young adults with type 1 diabetes, according to new data from a late-stage trial presented on Tuesday.

16 Sep 2014

Study shows Novo's new diabetes drug effective and safe for children

COPENHAGEN, Sept 16 - Novo Nordisk's new long-acting insulin Tresiba has been shown to be effective and safe for long-term use in children and young adults with type 1 diabetes, according to new data from a late-stage trial presented on Tuesday.

16 Sep 2014

U.S. FDA panel: Novo Nordisk's liraglutide safe, effective for obesity

WASHINGTON - Novo Nordisk's drug liraglutide is safe and effective enough to warrant approval for use in chronically obese patients with at least one weight-related health issue, an advisory panel to the U.S. Food and Drug Administration concluded on Thursday.

12 Sep 2014

Competitors

  Price Change
Sanofi SA (SASY.PA) €83.49 +0.06
Eli Lilly and Co (LLY.N) $64.68 0.00

Earnings vs. Estimates

Search Stocks